TriangleHEALTH PROFESSIONAL · SOURCE READING
Combined therapy for complicated hemangiomas
Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Benign Tumors / Infantile Hemangioma / Treatment of infantile hemangioma
Combined therapy is considered either at initiation of treatment in complicated lesions in which there is functional impairment or organ compromise or used at the end of systemic therapy to prevent hemangioma rebound. Further investigation of efficacy and safety is needed for these regimens.
Evidence (combined therapy for complicated hemangiomas):
A prospective randomized study that compared propranolol and 2 weeks of steroid therapy with propranolol alone revealed the following:[135]
Source links and citations
A prospective randomized study that compared propranolol and 2 weeks of steroid therapy with propranolol alone revealed the following:[135]
Decreased sizes of hemangiomas at 2, 4, and 8 weeks in the combined-therapy group but no statistical difference in the sizes at 6 months.
A prospective randomized study that compared timolol and propranolol with propranolol alone reported the following:[136]
Source links and citations
A prospective randomized study that compared timolol and propranolol with propranolol alone reported the following:[136]
Decreased color of the infantile hemangiomas in the timolol group but no difference in overall sizes of the infantile hemangiomas between the two treatment groups.
A prospective randomized study that compared timolol and propranolol with propranolol alone reported the following:[136]
Other studies have supported this combination.[137,138][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice